Tenaya Therapeutics (NASDAQ:TNYA) Given Buy Rating at HC Wainwright

Tenaya Therapeutics (NASDAQ:TNYA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $18.00 price objective on the stock.

Several other research analysts also recently issued reports on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a report on Friday, October 18th. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, Chardan Capital reissued a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a report on Wednesday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tenaya Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $17.33.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ:TNYA opened at $1.41 on Wednesday. The business has a fifty day moving average of $2.43 and a 200-day moving average of $2.71. Tenaya Therapeutics has a twelve month low of $0.99 and a twelve month high of $7.01. The firm has a market cap of $111.70 million, a PE ratio of -0.98 and a beta of 2.72.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.07. On average, analysts anticipate that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Synovus Financial Corp bought a new stake in Tenaya Therapeutics in the third quarter valued at about $28,000. SG Americas Securities LLC acquired a new position in shares of Tenaya Therapeutics during the 3rd quarter worth about $49,000. The Manufacturers Life Insurance Company increased its stake in shares of Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after acquiring an additional 7,000 shares during the last quarter. Algert Global LLC bought a new stake in shares of Tenaya Therapeutics in the 2nd quarter valued at about $74,000. Finally, XTX Topco Ltd raised its position in shares of Tenaya Therapeutics by 51.2% in the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after acquiring an additional 16,687 shares during the period. 90.54% of the stock is currently owned by institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.